BioCentury
ARTICLE | Top Story

Synageva proposes follow-on

March 5, 2014 1:08 AM UTC

Synageva BioPharma Corp. (NASDAQ:GEVA) proposed late Tuesday to sell 2 million shares in a follow-on underwritten by Goldman Sachs; JPMorgan; and Morgan Stanley. If sold at Synageva's close of $103.99 on Tuesday, before the company proposed the offering, Synageva would raise $208 million. The company's sebelipase alfa (formerly SBC-102) is in the Phase III ARISE trial for late onset lysosomal acid lipase (LAL) deficiency (cholesteryl ester storage disease), with data expected next half. By 1Q15, Synageva plans to submit a BLA to FDA and an MAA to EMA for the recombinant human LAL enzyme replacement therapy (ERT) to treat LAL deficiency. ...